全文获取类型
收费全文 | 7125篇 |
免费 | 652篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 57篇 |
儿科学 | 310篇 |
妇产科学 | 206篇 |
基础医学 | 979篇 |
口腔科学 | 180篇 |
临床医学 | 739篇 |
内科学 | 1533篇 |
皮肤病学 | 129篇 |
神经病学 | 792篇 |
特种医学 | 231篇 |
外国民族医学 | 1篇 |
外科学 | 1191篇 |
综合类 | 39篇 |
一般理论 | 4篇 |
预防医学 | 428篇 |
眼科学 | 146篇 |
药学 | 355篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 465篇 |
出版年
2022年 | 52篇 |
2021年 | 90篇 |
2020年 | 74篇 |
2019年 | 99篇 |
2018年 | 120篇 |
2017年 | 98篇 |
2016年 | 148篇 |
2015年 | 114篇 |
2014年 | 170篇 |
2013年 | 218篇 |
2012年 | 351篇 |
2011年 | 362篇 |
2010年 | 222篇 |
2009年 | 210篇 |
2008年 | 341篇 |
2007年 | 360篇 |
2006年 | 331篇 |
2005年 | 355篇 |
2004年 | 350篇 |
2003年 | 365篇 |
2002年 | 333篇 |
2001年 | 259篇 |
2000年 | 264篇 |
1999年 | 223篇 |
1998年 | 97篇 |
1997年 | 98篇 |
1996年 | 79篇 |
1995年 | 92篇 |
1994年 | 64篇 |
1993年 | 52篇 |
1992年 | 123篇 |
1991年 | 121篇 |
1990年 | 112篇 |
1989年 | 124篇 |
1988年 | 88篇 |
1987年 | 87篇 |
1986年 | 98篇 |
1985年 | 74篇 |
1984年 | 83篇 |
1983年 | 60篇 |
1982年 | 41篇 |
1981年 | 31篇 |
1980年 | 33篇 |
1979年 | 68篇 |
1978年 | 49篇 |
1977年 | 34篇 |
1976年 | 38篇 |
1975年 | 37篇 |
1974年 | 42篇 |
1972年 | 40篇 |
排序方式: 共有7792条查询结果,搜索用时 15 毫秒
171.
de Haas M; Kerst JM; van der Schoot CE; Calafat J; Hack CE; Nuijens JH; Roos D; van Oers RH; von dem Borne AE 《Blood》1994,84(11):3885-3894
In four healthy volunteers, we analyzed in detail the immediate in vivo effects on circulating neutrophils of subcutaneous administration of 300 micrograms of granulocyte colony-stimulating factor (G-CSF). Neutrophil activation was assessed by measurement of degranulation. Mobilization of secretory vesicles was shown by a decrease in leukocyte alkaline phosphatase content of the circulating neutrophils. Furthermore, shortly postinjection, Fc gamma RIII was found to be upregulated from an intracellular pool that we identified by immunoelectron microscopy as secretory vesicles. Intravascular release of specific granules was shown by increased plasma levels of lactoferrin and by upregulation of the expression of CD66b and CD11b on circulating neutrophils. Moreover, measurement of fourfold elevated plasma levels of elastase, bound to its physiologic inhibitor alpha 1- antitrypsin, indicated mobilization of azurophil granules. However, no expression of CD63, a marker of azurophil granules, was observed on circulating neutrophils. G-CSF--induced mobilization of secretory vesicles and specific granules could be mimicked in whole blood cultures in vitro, in contrast to release of azurophil granules. Therefore, we postulate that the most activated neutrophils leave the circulation, as observed shortly postinjection, and undergo subsequent stimulation in the endothelial microenvironment, resulting in mobilization of azurophil granules. Our data demonstrate that G-CSF should be regarded as a potent immediate activator of neutrophils in vivo. 相似文献
172.
Srikanth Vedachalam Gokulakrishnan Balasubramanian Garrie J Haas Somashekar G Krishna 《World journal of gastroenterology : WJG》2020,26(20):2550-2558
Left ventricular assist devices(LVAD) are increasingly become common as life prolonging therapy in patients with advanced heart failure. Current devices are now used as definitive treatment in some patients given the improved durability of continuous flow pumps. Unfortunately, continuous flow LVADs are fraught with complications such as gastrointestinal(GI) bleeding that are primarily attributed to the formation of arteriovenous malformations. With frequent GI bleeding, antiplatelet and anticoagulation therapies are usually discontinued increasing the risk of life-threatening events. Small bowel bleeds account for 15%as the source and patients often undergo multiple endoscopic procedures.Treatment strategies include resuscitative measures and endoscopic therapies.Medical treatment is with octreotide. Novel treatment options include thalidomide, angiotensin converting enzyme inhibitors/angiotensin Ⅱ receptor blockers, estrogen-based hormonal therapies, doxycycline, desmopressin and bevacizumab. Current research has explored the mechanism of frequent GI bleeds in this population, including destruction of von Willebrand factor,upregulation of tissue factor, vascular endothelial growth factor, tumor necrosis factor-α, tumor growth factor-β, and angiopoetin-2, and downregulation of angiopoetin-1. In addition, healthcare resource utilization is only increasing in this patient population with higher admissions, readmissions, blood product utilization, and endoscopy. While some of the novel endoscopic and medical therapies for LVAD bleeds are still in their development stages, these tools will yet be crucial as the number of LVAD placements will likely only increase in the coming years. 相似文献
173.
174.
175.
176.
Brandon N. Nicolay Paul S. Danielian Filippos Kottakis John D. Lapek Jr Ioannis Sanidas Wayne O. Miles Mantre Dehnad Katrin Tsch?p Jessica J. Gierut Amity L. Manning Robert Morris Kevin Haigis Nabeel Bardeesy Jacqueline A. Lees Wilhelm Haas Nicholas J. Dyson 《Genes & development》2015,29(17):1875-1889
177.
Studies of immunosuppressive therapy, particularly mycophenolate mofetil (MMF), in membranous lupus nephritis (MLN) are limited. We report on our experience with primary (first-line) MMF therapy to induce and sustain renal remission in MLN with and without a concurrent proliferative lesion. Systemic lupus erythematosus (SLE) patients were studied, retrospectively, if treated with MMF for newly diagnosed MLN. Complete remission was defined as proteinuria less than 0.5 g/24 h, inactive urine sediment and normal estimated glomerular filtration rate. Response in pure MLN (Group I, n=10) was compared with mixed MLN and proliferative lupus nephritis (Group II, n=19). By 12 months, 4 (40%) patients in Group I and 7 (36.8%) in Group II achieved complete remission (P=0.87). One (10%) patient in Group I and 2 (10.5%) in Group II had worsening renal disease (P=0.97). Mean time to remission was more than seven months in both groups. The remaining patients had stable disease without improvement or worsening. Only 2 of 11 achieving initial remission had a relapse with an average of 28 months of follow-up after remission. Self-limited gastrointestinal symptoms occurred in 12 patients, none requiring withdrawal of the drug. Mycophenolate mofetil as a primary therapy in MLN was successful in inducing complete remission in about 40% of MLN, particularly in patients with mild proteinuria. However, 12 months of therapy was necessary for best outcomes. Response rate was not different in the presence or absence of a proliferative lesion. 相似文献
178.
OBJECTIVE: Obese subjects have functional growth hormone deficiency (GHD). Recombinant human GH (rhGH) treatment of pituitary GHD improves serum levels of leptin, adiponectin and C-reactive protein (CRP). This study was undertaken to determine whether these rhGH-induced changes occur in obese subjects during rhGH supplementation. DESIGN: Randomized double-blind placebo-controlled trial of low-dose rhGH (200 microg/day for the first month, then 400 microg/day for men and 600 microg/day for women thereafter) or placebo supplementation as an adjuvant to a standard weight loss program. SUBJECTS: Forty healthy obese subjects, 28 premenopausal menstruating women (35+/-7 SD years) and 12 men (37+/-6 years). MEASUREMENTS: Body weight, BMI, body composition (assessed by dual energy X-ray absorptiometry [DEXA]), and serum levels of glucose, insulin, IGF-I, IGFBP-3, insulin resistance index (homeostasis modal assessment [HOMA]), leptin, CRP and adiponectin were performed at baseline and at 6 months. RESULTS: For similar entry BMI values, women when compared with men had higher percent body fat (BF) (43.5+/-4.6% vs. 29.8+/-4.0%, p<0.001), higher leptin levels (16.9+/-8.4 microg/L vs. 4.2+/-3.0 microg/L, p<0.001), and higher CRP levels (13.8+/-16.8 mg/L vs. 2.4+/-3.2mg/L, p=0.04). Serum levels of leptin and CRP, but not adiponectin, correlated significantly with BF in both sexes. Recombinant human GH treatment increased levels of IGF-I Z-Score between baseline and 6 months (from -0.7+/-0.9 SD to 0.1+/-1.1 SD, p=0.01) and modestly decreased BF (from 38.4+/-7.8% to 35.6+/-7.5%, p=0.046). Despite increased IGF-I, there were no differences between rhGH and placebo with regard to changes in leptin, CRP, or adiponectin. CONCLUSION: It is concluded that in obesity, although rhGH treatment significantly increases IGF-I and modestly reduces body fat, the lack of significant changes in serum leptin, adiponectin or CRP levels suggests that rhGH treatment does not have a significant effect on these serum markers of adiposity. 相似文献
179.
Enhanced sensitivity of hippocampal pyramidal neurons from mdx mice to hypoxia-induced loss of synaptic transmission.
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M F Mehler K Z Haas J A Kessler P K Stanton 《Proceedings of the National Academy of Sciences of the United States of America》1992,89(6):2461-2465
The gene at the Duchenne/Becker muscular dystrophy locus encodes dystrophin, a member of a protein superfamily that links the actin cytoskeleton to transmembrane plasmalemmal proteins. In mature skeletal myocytes, the absence of dystrophin is associated with decreased membrane stability, altered kinetics of several calcium channels, and increased intracellular calcium concentration. In the central nervous system, dystrophin is restricted to specific neuronal populations that show heightened susceptibility to excitotoxic damage and is localized in proximal dendrites and the neuronal somata. We report that CA1 pyramidal neurons in a hippocampal slice preparation from a dystrophin-deficient mouse genetic model of Duchenne muscular dystrophy (the mdx mouse) exhibit significant increased susceptibility to hypoxia-induced damage to synaptic transmission. This selective vulnerability was substantially ameliorated by pretreatment with diphenylhydantoin, an anticonvulsant that blocks both sodium-dependent action potentials and low-threshold transient calcium conductances. These findings suggest that dystrophin deficiency could predispose susceptible neuronal populations to cumulative hypoxic insults that may contribute to the development of cognitive deficits in Duchenne/Becker muscular dystrophy patients and that the effects of such periods of hypoxia may be pharmacologically remediable. 相似文献
180.
M. Witzens G. Egerer D. Stahl E. Werle H. Goldschmidt R. Haas 《Annals of hematology》1998,77(5):231-234
We report here for the first time a patient with μ heavy-chain disease (HCD), hyperimmunoglobulinemia, and a positive direct
antiglobulin test (DAT, Coombs test). The heavy-chain diseases involve the proliferation of lymphoplasma cells of B cell origin
and are characterized by the production of incomplete heavy chains devoid of light chains. The association of μ heavy-chain
disease with either hyperglobulinemia or a positive DAT has not been reported in the literature to date. In this patient,
immunofixation of serum proteins with monospecific antisera to α-, γ-, μ,- or δ-chains and to κ- and λ-chains revealed a precipitation
band with antibody to IgM, but not with κ and λ light-chain antibodies, indicating μ heavy-chain disease. Hyperglobulinemia
was present, which is very uncommon for HCD. A DAT of the patient's red blood cells (RBC) was found to be strongly positive
for anti-IgG but negative for anti-IgM, -IgA, -C3c, and -C3d. However, when the eluate from the patient's red blood cells
was investigated with nephelometry, it was found to contain antigens reactive with anti-γ as well with anti-μ-antiserum. When
a DAT was performed with a randomly chosen test cell incubated with the eluate, the antibody-containing eluate was shown to
react with anti-IgG as well as with anti-IgM-antiserum. In summary, the eluate from the patient's RBCs contained IgG and an
immunoglobulin structure reactive with anti-IgM in an RBC agglutination assay as well as with anti-μ antiserum in a nephelometric
investigation. Whether this IgM on the patient's erythrocytes is penta- or oligomeric, complete IgM, or the heavy chain cannot
be concluded from these observations.
Received: May 15, 1998 / Accepted: August 24, 1998 相似文献